Epic Sciences Receives CAP Accreditation

Jan 11, 2016, 08:01 ET from Epic Sciences

SAN DIEGO, Jan. 11, 2016 /PRNewswire/ -- Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. The CAP Laboratory Accreditation Program is recognized by the United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.

"Our investment in a high-throughput, CLIA/CAP laboratory will give drug developers and academic investigators alike the ability to scale Epic Sciences' circulating tumor cell (CTC) based liquid biopsy tests from small observational studies to large Phase III trials," said Murali Prahalad, Ph.D., President and CEO of Epic Sciences.

Epic Sciences has analyzed more than 10,000 blood samples from cancer patients and is in use in more than 58 active clinical trials. The identification and characterization of CTCs from a liquid biopsy, allows for the development of companion diagnostics that match the right patients to the right therapies at the right time.

Epic Sciences' no cell left behind® platform identifies CTCs in an unbiased manner, without enrichment or depletion on any parameter.  It has the capability to detect all categories of CTCs in the blood, and can analyze single CTCs for genomic, proteomic, and morphologic markers.

About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic Sciences' no cell left behind® technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.

Epic Sciences Investor Contact:
Michael Rodriguez, CFO, Epic Sciences, ir@epicsciences.com, +1.858.356.6610

Epic Sciences Media Contact:
Ryan Ferrell, HDMZ, epic@hdmz.com, +1.312.506.5202


SOURCE Epic Sciences